Association between risk of brucellosis and genetic variations in MicroRNA-146a.
Brucellosis
Genetic variations
miR-146a
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
16 Oct 2021
16 Oct 2021
Historique:
received:
29
03
2021
accepted:
08
10
2021
entrez:
17
10
2021
pubmed:
18
10
2021
medline:
21
10
2021
Statut:
epublish
Résumé
Single nucleotide polymorphisms (SNPs) are the most common types of DNA changes in the human genome that leading to phenotypic differences in humans. MicroRNAs (miRNAs) are usually affected by various bacterial infections, and they are involved in controlling the immune responses. MicroRNA-146a (miR-146a) plays an essential role in the development of infectious and inflammatory diseases. The aim of the present study was to investigate the association between risk of brucellosis and genetic variations in miR-146a. This case-control study was conducted on 108 Brucellosis patients and 108 healthy controls. We genotyped two SNPs (rs2910164 and rs57095329) of the miR-146a using tetra-primer amplification refractory mutation system-polymerase chain reaction (T-ARMS-PCR) and restriction fragment length polymorphism-polymerase chain reaction (RFLP-PCR) methods. The rs2910164 SNP was significantly associated with brucellosis in co-dominant [OR = 4.27, 95% CI = (2.35-7.79, P = 0.001] and dominant [OR = 3.52, 95% CI = (1.97-6.30, P = 0.001] models. Co-dominant (P = 0.047) and recessive (P = 0.018) models were significant at position rs57095329 between the two groups of patient and healthy. The A C haplotype (rs2910164 and rs57095329) was associated with brucellosis in the assessed population [OR (95% CI) = 1.98 (1.22-3.20), P = 0.0059]. Consequently, our study demonstrated significant differences in genotype and haplotype frequencies of miR-146a variants between brucellosis patients and controls. Further studies on the larger sample sizes are required to verify the observed associations.
Sections du résumé
BACKGROUND
BACKGROUND
Single nucleotide polymorphisms (SNPs) are the most common types of DNA changes in the human genome that leading to phenotypic differences in humans. MicroRNAs (miRNAs) are usually affected by various bacterial infections, and they are involved in controlling the immune responses. MicroRNA-146a (miR-146a) plays an essential role in the development of infectious and inflammatory diseases. The aim of the present study was to investigate the association between risk of brucellosis and genetic variations in miR-146a.
METHODS
METHODS
This case-control study was conducted on 108 Brucellosis patients and 108 healthy controls. We genotyped two SNPs (rs2910164 and rs57095329) of the miR-146a using tetra-primer amplification refractory mutation system-polymerase chain reaction (T-ARMS-PCR) and restriction fragment length polymorphism-polymerase chain reaction (RFLP-PCR) methods.
RESULTS
RESULTS
The rs2910164 SNP was significantly associated with brucellosis in co-dominant [OR = 4.27, 95% CI = (2.35-7.79, P = 0.001] and dominant [OR = 3.52, 95% CI = (1.97-6.30, P = 0.001] models. Co-dominant (P = 0.047) and recessive (P = 0.018) models were significant at position rs57095329 between the two groups of patient and healthy. The A C haplotype (rs2910164 and rs57095329) was associated with brucellosis in the assessed population [OR (95% CI) = 1.98 (1.22-3.20), P = 0.0059].
CONCLUSIONS
CONCLUSIONS
Consequently, our study demonstrated significant differences in genotype and haplotype frequencies of miR-146a variants between brucellosis patients and controls. Further studies on the larger sample sizes are required to verify the observed associations.
Identifiants
pubmed: 34656082
doi: 10.1186/s12879-021-06775-4
pii: 10.1186/s12879-021-06775-4
pmc: PMC8520608
doi:
Substances chimiques
MIRN146 microRNA, human
0
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1070Subventions
Organisme : Hamadan University of Medical Sciences;
ID : 9711307368
Organisme : Hamadan University of Medical Sciences;
ID : 9711307368
Organisme : Hamadan University of Medical Sciences;
ID : 9711307368
Organisme : Hamadan University of Medical Sciences;
ID : 9711307368
Organisme : Hamadan University of Medical Sciences;
ID : 9711307368
Organisme : Hamadan University of Medical Sciences;
ID : 9711307368
Organisme : Hamadan University of Medical Sciences;
ID : 9711307368
Informations de copyright
© 2021. The Author(s).
Références
Cell Mol Life Sci. 2006 Oct;63(19-20):2229-36
pubmed: 16964579
Int J Mol Sci. 2020 Mar 29;21(7):
pubmed: 32235299
Mediators Inflamm. 2014;2014:916202
pubmed: 24701036
Genes Dev. 2011 Sep 15;25(18):1881-94
pubmed: 21896651
Cell Biochem Biophys. 2014 Mar;68(2):259-66
pubmed: 23794009
BMC Infect Dis. 2015 Feb 05;15:41
pubmed: 25650003
Mol Immunol. 2011 May;48(9-10):1084-90
pubmed: 21367459
Int J Antimicrob Agents. 2018 Mar;51(3):365-369
pubmed: 28826825
Cells. 2014 Aug 22;3(3):883-98
pubmed: 25153164
IUBMB Life. 2020 Sep;72(9):1856-1869
pubmed: 32516518
J Comp Pathol. 2009 Feb-Apr;140(2-3):149-57
pubmed: 19111839
Int J Infect Dis. 2007 Nov;11(6):496-500
pubmed: 17344084
World J Gastroenterol. 2012 Jun 14;18(22):2827-31
pubmed: 22719192
Cell Microbiol. 2013 Sep;15(9):1496-507
pubmed: 23795564
Pathol Oncol Res. 2020 Jan;26(1):193-200
pubmed: 29594807
Int J Cancer. 2010 Mar 15;126(6):1283-90
pubmed: 19877123
Int J Cancer. 2011 Jul 1;129(1):180-91
pubmed: 20824701
Front Immunol. 2015 Jan 29;6:19
pubmed: 25688245
Nucleic Acids Res. 1988 Feb 11;16(3):1215
pubmed: 3344216
Mol Immunol. 2013 Mar;53(3):265-9
pubmed: 22964481
Exp Cell Res. 2017 Sep 15;358(2):120-128
pubmed: 28606793
BMC Res Notes. 2015 Sep 04;8:405
pubmed: 26337599
Scand J Immunol. 2010 Apr;71(4):227-31
pubmed: 20384865
Cell. 1993 Dec 3;75(5):843-54
pubmed: 8252621
RNA Biol. 2012 Jun;9(6):742-50
pubmed: 22664920
Front Cell Infect Microbiol. 2016 Aug 03;6:79
pubmed: 27536558
J Immunol. 2011 Oct 1;187(7):3578-86
pubmed: 21880981
Lancet Oncol. 2012 Jun;13(6):e249-58
pubmed: 22652233
Nat Protoc. 2007;2(11):2649-54
pubmed: 18007600
PLoS One. 2014 Jan 27;9(1):e87467
pubmed: 24475294
Carcinogenesis. 2008 Nov;29(11):2126-31
pubmed: 18711148
Cell Physiol Biochem. 2015;35(1):281-91
pubmed: 25591770
Cancer J. 2012 May-Jun;18(3):223-31
pubmed: 22647358
PLoS Pathog. 2017 Apr 10;13(4):e1006327
pubmed: 28394930
Oral Oncol. 2012 May;48(5):404-8
pubmed: 22182931
Lab Med. 2019 Jan 1;50(1):34-41
pubmed: 30060033
Semin Cell Dev Biol. 2017 May;65:11-19
pubmed: 27381344
Nat Rev Immunol. 2010 Feb;10(2):111-22
pubmed: 20098459
Front Immunol. 2014 Nov 21;5:578
pubmed: 25484882
Immunol Invest. 2016;45(2):107-15
pubmed: 26849072
Int J Mol Sci. 2012;13(1):1173-85
pubmed: 22312311
PLoS One. 2014 Feb 25;9(2):e89019
pubmed: 24586483
Cell Host Microbe. 2015 Mar 11;17(3):345-356
pubmed: 25683052
Inflammation. 2017 Jun;40(3):995-1005
pubmed: 28303416
PLoS One. 2013 Apr 17;8(4):e61250
pubmed: 23613822
Seizure. 2015 Apr;27:60-5
pubmed: 25891929
Trends Microbiol. 2019 Mar;27(3):206-218
pubmed: 30477908
Arch Immunol Ther Exp (Warsz). 2016 Dec;64(Suppl 1):131-136
pubmed: 28083614
J Adv Res. 2016 May;7(3):491-8
pubmed: 27222754
Ann Rheum Dis. 2014 Jan;73(1):170-6
pubmed: 23268366
PLoS Negl Trop Dis. 2014 Sep 04;8(9):e3099
pubmed: 25187983
PLoS One. 2014 Mar 21;9(3):e91199
pubmed: 24658012
Proc Natl Acad Sci U S A. 2016 Oct 11;113(41):E6172-E6181
pubmed: 27681624
Hum Vaccin Immunother. 2013 Aug;9(8):1673-8
pubmed: 23807362
Nat Commun. 2014 Apr 10;5:3619
pubmed: 24717937
Annu Rev Microbiol. 2011;65:523-41
pubmed: 21939378
J Dig Dis. 2016 Mar;17(3):169-74
pubmed: 26896831
PLoS Genet. 2011 Jun;7(6):e1002128
pubmed: 21738483
Nat Rev Drug Discov. 2014 Aug;13(8):622-38
pubmed: 25011539
Immunol Lett. 2012 Jan 30;141(2):165-8
pubmed: 22033216
Biochem Biophys Res Commun. 2005 Jun 17;331(4):1439-44
pubmed: 15883035
Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12481-6
pubmed: 16885212
Nat Rev Immunol. 2011 Mar;11(3):163-75
pubmed: 21331081
FEBS Lett. 2014 Nov 17;588(22):4140-7
pubmed: 25128459